Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Overview
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AstraZeneca Plc
IMPACT Therapeutics Inc
InteR Technologies BV
Merck KGaA
Shuttle Pharmaceuticals Inc
XRad Therapeutics Inc
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Drug Profiles
AZD-1390 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IMP-08 - Drug Profile
Product Description
Mechanism Of Action
INT-C4/5C4 - Drug Profile
Product Description
Mechanism Of Action
KU-55933 - Drug Profile
Product Description
Mechanism Of Action
M-4076 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit ATM for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
SP-1161 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XRD-0394 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Dormant Products
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Discontinued Products
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Aug 25, 2021: XRad Therapeutics announces first patient dosed in phase 1a clinical trial of XRD-0394 for metastatic, locally-advanced or recurrent solid tumors
Nov 04, 2020: Shuttle Pharmaceuticals awarded a new patent for dual function HDAC molecules for HDAC inhibition and ataxia telangiectasia mutated activation for cancer treatment
May 07, 2019: Xstrahl In Action: ATM inhibitors radiosensitize and improves survival of preclinical brain tumor models
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by IMPACT Therapeutics Inc, 2022
Pipeline by InteRNA Technologies BV, 2022
Pipeline by Merck KGaA, 2022
Pipeline by Shuttle Pharmaceuticals Inc, 2022
Pipeline by XRad Therapeutics Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022